全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Chi Hoon Park , Sung Yun Cho , Jae Du Ha ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:Abstract(#br) Background(#br)c-Met signaling has been implicated in oncogenesis especially in cells with c - met gene amplification. Since 20 % of gastric cancer patients show high level of c-Met expression, c-Met has been identified as a good candidate for targeted therapy in ga...
作者:Muhamed Baljevic , Shadia Zaman , Veerabhadran Baladandayuthapani ...
来源:[J].Annals of Hematology(IF 2.866), 2017, Vol.96 (6), pp.977-985Springer
摘要:The hepatocyte growth factor/c-MET pathway has been implicated in the pathobiology of multiple myeloma, and c-MET inhibitors induce myeloma cell apoptosis, suggesting that they could be useful clinically. We conducted a phase II study with the c-MET inhibitor tivantinib in patien...
作者:Stefan Wiehr , Oliver Ahsen , Lars Röse ...
来源:[J].Molecular Imaging and Biology(IF 3.095), 2013, Vol.15 (2), pp.203-211Springer
摘要:Abstract(#br) Purpose(#br)Here, we describe the efficacy of the novel small molecule c-Met inhibitor BAY 853474 in reducing tumor growth in the Hs746T gastric cancer xenograft model and tested the suitability of 2-deoxy-2-[ 18 F]fluoro- d -glucose ([ 18 F]FDG) versus 3′-deox...
作者:Yoon-Koo Kang , Kei Muro , Min-Hee Ryu ...
来源:[J].Investigational New Drugs(IF 3.498), 2014, Vol.32 (2), pp.355-361Springer
摘要:Summary(#br) Background Tivantinib is a selective, non-ATP competitive, small-molecule inhibitor of c-Met and is under development in several cancers including non-small cell lung and hepatocellular carcinoma. Activation of c-Met has been frequently found in metastatic gastric ca...
作者:Stephen K. Chia , Susan L. Ellard , Mihaela Mates ...
来源:[J].Breast Cancer Research(IF 5.872), 2017, Vol.19 (1)Springer
摘要:The mechanisms of resistance to anti-human epidermal growth factor receptor 2 (HER 2) therapies are unclear but may include the tyrosine-protein kinase Met (c-Met), vascular endothelial growth factor (VEGF) and AXL pathways. Foretinib is an inhibitor of c-Met, VEGF receptor 2 (VE...
作者:Tu William , Zhu Chunfang , Clark Curtis ...
来源:[J].BMC Cancer(IF 3.333), 2010, Vol.10 (1), pp.556DOAJ
摘要:Abstract Background Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (AR) signalling. This sugges...
作者:Hongliang Yu , Xiaoying Li , Shaoqian Sun ...
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2012, Vol.427 (3), pp.659-665Elsevier
摘要:... c-Met overexpression plays a key role in prostate cancer tumorigenesis and disease progression. Here, we demonstrate that c-Met inhibition by SU11274 could significantly suppress cell survival and proliferation as well as enhance the radiosensitivity of DU145 cells. The under...
作者:Jo Eun Byeol , Lee Young Sang , Lee Hyunjoo ...
来源:[J].BMC cancer(IF 3.333), 2019, Vol.19 (1), pp.496PubMed
摘要:... In the present study, we investigated the effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment, and of combination treatment using TRAIL and a c-Met inhibitor on cell viability and apoptosis in LPS and DDLPS cell lines of tumor necrosis factor-r...
作者:Christensen James G , Clark Curtis , Zhu Chunfang ...
来源:[J].BMC Cancer(IF 3.333), 2010, Vol.10 (1)DOAJ
摘要:Abstract Background Aberrant expression of HGF/SF and its receptor, c-Met, often correlates with advanced prostate cancer. Our previous study showed that expression of c-Met in prostate cancer cells was increased after attenuation of androgen receptor (AR) signalling. This sugges...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×